

# Resource Summary Report

Generated by [dkNET](#) on Sep 14, 2026

## GP2d

RRID:CVCL\_2450

Type: Cell Line

### Proper Citation

RRID:CVCL\_2450

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_2450](https://web.expasy.org/cellosaurus/CVCL_2450)

**Proper Citation:** RRID:CVCL\_2450

**Description:** Cell line GP2d is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Colon adenocarcinoma

**Defining Citation:** [PMID:7601566](#), [PMID:10051639](#), [PMID:10737795](#), [PMID:11226274](#), [PMID:16418264](#), [PMID:18258742](#), [PMID:20164919](#), [PMID:20606684](#), [PMID:22460905](#), [PMID:23272949](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:29101300](#), [PMID:30894373](#), [PMID:31068700](#)

**Comments:** Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** GP2d

**Synonyms:** Gp2d, Gp2D, GP2D

**Cross References:** CLO:CLO\_0003554, CLO:CLO\_0009961, EFO:EFO\_0006575, CLDB:cl1511, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03472980, BioSample:SAMN10988004, cancercellines:CVCL\_2450, Cell\_Model\_Passport:SIDM00536, ColonAtlas:GP2d, Cosmic:907292, Cosmic:948863, Cosmic:995380, Cosmic:1223138, Cosmic:1609504, Cosmic:2301973, DepMap:ACH-000982, ECACC:95090714, EGA:EGAS00001000610,

EGA:EGAS00001002554, GEO:GSM887027, GEO:GSM888097, GEO:GSM1346870, GEO:GSM1374483, GEO:GSM1448105, IARC\_TP53:21352, LiGeA:CCLE\_010, LINCS\_LDP:LCL-1188, PharmacoDB:Gp2D\_410\_2019, PRIDE:PXD005354, PRIDE:PXD005355, Progenetix:CVCL\_2450, Wikidata:Q54871632

**ID:** CVCL\_2450

**Record Creation Time:** 20220427T220218+0000

**Record Last Update:** 20260913T003751+0000

---

## Ratings and Alerts

No rating or validation information has been found for GP2d.

No alerts have been found for GP2d.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 7 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Yuan T, et al. (2026) USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit. *Acta pharmaceutica Sinica. B*, 16(1), 322.

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.

Thielen N, et al. (2026) High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. *NPJ precision oncology*, 10(1).

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Fan W, et al. (2025) Ribosomal RNA transcription regulates splicing through ribosomal protein RPL22. *Cell chemical biology*, 32(7), 908.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Candiello E, et al. (2023) MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis. *Molecular oncology*.